These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 27092564)
21. Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*. Stephan C; Hill A; Sawyer W; van Delft Y; Moecklinghoff C HIV Med; 2013 May; 14(5):284-92. PubMed ID: 23171153 [TBL] [Abstract][Full Text] [Related]
23. The pipeline: three to watch. Hawes J BETA; 2004; 16(4):13-5. PubMed ID: 15386838 [TBL] [Abstract][Full Text] [Related]
24. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Eron J; Yeni P; Gathe J; Estrada V; DeJesus E; Staszewski S; Lackey P; Katlama C; Young B; Yau L; Sutherland-Phillips D; Wannamaker P; Vavro C; Patel L; Yeo J; Shaefer M; Lancet; 2006 Aug; 368(9534):476-82. PubMed ID: 16890834 [TBL] [Abstract][Full Text] [Related]
25. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS; J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763 [TBL] [Abstract][Full Text] [Related]
32. Current status of antiretroviral therapy. Temesgen Z; Warnke D; Kasten MJ Expert Opin Pharmacother; 2006 Aug; 7(12):1541-54. PubMed ID: 16872258 [TBL] [Abstract][Full Text] [Related]
33. New targets and new drugs in the treatment of HIV. López-Aldeguer J; Aguirrebengoa K; Arribas JR; Esté JA; Kindelán JM Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():25-40. PubMed ID: 16373002 [TBL] [Abstract][Full Text] [Related]
34. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load. Bickel M; Rickerts V; Stephan C; Jacobi V; Rottmann C; Dauer B; Carlebach A; Thalhammer A; Miller V; Staszweski S HIV Med; 2005 May; 6(3):179-84. PubMed ID: 15876284 [TBL] [Abstract][Full Text] [Related]
35. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA; N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850 [TBL] [Abstract][Full Text] [Related]
36. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764 [TBL] [Abstract][Full Text] [Related]
38. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients. Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820 [TBL] [Abstract][Full Text] [Related]
39. Emtricitabine: new preparation. An antiretroviral very similar to lamivudine. Prescrire Int; 2005 Apr; 14(76):54-6. PubMed ID: 15875341 [TBL] [Abstract][Full Text] [Related]
40. New antiretroviral agents and the complexity of treatment practices. Smith D J HIV Ther; 2008 Jun; 13(2):25-6. PubMed ID: 18953270 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]